Alvotech And Advanz Claim A Global First With Golimumab Filing

Simponi Biosimilar Application Accepted By EMA; Approval Anticipated In Q4 2025

 
• By Dave Wallace

Alvotech and Advanz have celebrated a worldwide first with the European Medicines Agency’s acceptance of an application for their partnered golimumab biosimilar rival to Simponi.

Advanz and Alvotech are the first to file golimumab worldwide (Shutterstock)

More from Biosimilars

More from Generics Bulletin